New Data on Zogenix’s ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting
22 nov. 2016 16h05 HE
|
Zogenix, Inc.
Interim Results of Investigator Initiated Phase 2 study of ZX008 in Lennox Gastaut Syndrome to be PresentedUpdate from Ongoing Open-Label Prospective Study of ZX008 in Dravet Syndrome Will Also be...
Zogenix to Participate in Oppenheimer Life Sciences Summit 2016
22 nov. 2016 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Participate in Stifel 2016 Healthcare Conference
08 nov. 2016 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results
07 nov. 2016 16h01 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Release Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 7
31 oct. 2016 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Participate in Two Upcoming Investor Conferences
20 sept. 2016 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to have Significant Presence at 12th European Congress on Epileptology
08 sept. 2016 16h05 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
09 août 2016 16h01 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9
02 août 2016 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
21 juin 2016 08h00 HE
|
Zogenix, Inc.
- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc....